The report “ Global Antibody Drug Conjugate Market, By Technology (Cleavable Linker and Non-Cleavable Linker), By Application (Blood Cancer, Ovarian Cancer, Lung Cancer and Brain Tumor), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Trends, Analysis, and Forecast till 2030”
Key Highlights:
- In June 2019, Seattle Genetics and Astellas Pharma, Inc. announced first cohort of pivotal phase 2 clinical trial called EV-201 which is antibody-drug conjugate rapidly shrunk tumor in most patients.
- In March 2019, LegoChem Bioscience and Takeda collaborated and got license to develop an antibody-drug conjugate which is used for immune-oncology.
To know the upcoming trends and insights prevalent in this market, click the link below:
https://www.prophecymarketinsights.com/market_insight/Global-Antibody-Drug-Conjugate-Market-4671
Key Market Insights from the report:
The global antibody drug conjugate market accounted for US$ 3.3 billion in 2020 and is estimated to be US$ 27.0 billion by 2030 and is anticipated to register a CAGR of 23.5%. The Global Antibody Drug Conjugate Market is segmented based on the technology, application, distribution channel and region.
- On the basis of Technology, the global antibody drug conjugate market is segmented into cleavable linker and non-cleavable linker.
- Based on application, the target market is segmented into Blood Cancer, Ovarian Cancer, Lung Cancer and Brain Tumor.
- On the basis of distribution channel, the target market is segmented into hospital pharmacies, online pharmacies and others.
- By region, the Global Antibody Drug Conjugate Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe is the worldwide leader in the antibody drug conjugate in terms of revenue, due to the developed healthcare system and health awareness among people.
Competitive Landscape:
The key players operating in the global antibody drug conjugate market includes F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
Contact Us:
Sales
Prophecy Market Insights
Email- sales@prophecymarketinsights.com